X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with Cadila Healthcare - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs CADILA HEALTHCARE - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. CADILA HEALTHCARE FRESENIUS KABI ONCO./
CADILA HEALTHCARE
 
P/E (TTM) x 22.1 32.7 67.8% View Chart
P/BV x 3.1 6.5 48.1% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 FRESENIUS KABI ONCO.   CADILA HEALTHCARE
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
CADILA HEALTHCARE
Mar-17
FRESENIUS KABI ONCO./
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs176460 38.3%   
Low Rs79305 25.7%   
Sales per share (Unadj.) Rs37.792.1 40.9%  
Earnings per share (Unadj.) Rs5.114.8 34.4%  
Cash flow per share (Unadj.) Rs6.718.5 36.4%  
Dividends per share (Unadj.) Rs03.20 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs42.568.0 62.6%  
Shares outstanding (eoy) m158.231,023.74 15.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.44.2 81.3%   
Avg P/E ratio x25.025.8 96.8%  
P/CF ratio (eoy) x18.920.7 91.4%  
Price / Book Value ratio x3.05.6 53.2%  
Dividend payout %021.6 0.0%   
Avg Mkt Cap Rs m20,135391,581 5.1%   
No. of employees `0001.216.9 6.8%   
Total wages/salary Rs m70315,002 4.7%   
Avg. sales/employee Rs Th5,176.25,594.5 92.5%   
Avg. wages/employee Rs Th610.4890.1 68.6%   
Avg. net profit/employee Rs Th699.6899.9 77.7%   
INCOME DATA
Net Sales Rs m5,96394,295 6.3%  
Other income Rs m181,286 1.4%   
Total revenues Rs m5,98195,581 6.3%   
Gross profit Rs m1,43019,036 7.5%  
Depreciation Rs m2583,750 6.9%   
Interest Rs m-26450 -5.8%   
Profit before tax Rs m1,21616,122 7.5%   
Minority Interest Rs m0338 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-68-3 2,270.0%   
Tax Rs m3421,289 26.5%   
Profit after tax Rs m80615,168 5.3%  
Gross profit margin %24.020.2 118.8%  
Effective tax rate %28.18.0 351.9%   
Net profit margin %13.516.1 84.0%  
BALANCE SHEET DATA
Current assets Rs m5,10260,223 8.5%   
Current liabilities Rs m2,38553,058 4.5%   
Net working cap to sales %45.67.6 599.5%  
Current ratio x2.11.1 188.4%  
Inventory Days Days15070 214.9%  
Debtors Days Days11388 128.5%  
Net fixed assets Rs m5,14872,984 7.1%   
Share capital Rs m1581,024 15.4%   
"Free" reserves Rs m6,55668,576 9.6%   
Net worth Rs m6,73269,600 9.7%   
Long term debt Rs m95224,684 3.9%   
Total assets Rs m10,388152,207 6.8%  
Interest coverage x-45.836.8 -124.3%   
Debt to equity ratio x0.10.4 39.9%  
Sales to assets ratio x0.60.6 92.7%   
Return on assets %7.510.3 73.2%  
Return on equity %12.021.8 54.9%  
Return on capital %14.617.9 81.4%  
Exports to sales %74.50-   
Imports to sales %24.80-   
Exports (fob) Rs m4,441NA-   
Imports (cif) Rs m1,477NA-   
Fx inflow Rs m5,29821,280 24.9%   
Fx outflow Rs m1,77210,874 16.3%   
Net fx Rs m3,52510,406 33.9%   
CASH FLOW
From Operations Rs m1,27413,495 9.4%  
From Investments Rs m-1,204-29,103 4.1%  
From Financial Activity Rs m-19623,158 -0.8%  
Net Cashflow Rs m-1267,556 -1.7%  

Share Holding

Indian Promoters % 0.0 74.8 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 8.3 3.6%  
FIIs % 9.6 5.9 162.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 11.0 82.7%  
Shareholders   42,599 44,069 96.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   SUN PHARMA  DR. REDDYS LAB  NOVARTIS  UNICHEM LAB  MERCK LTD  

Compare FRESENIUS KABI ONCO. With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Of Rising Stock Markets, Reduction in Government's Additional Borrowing, and Top Cues in Focus Today(Pre-Open)

Share markets in India closed on a strong note yesterday. At the closing bell yesterday, the BSE Sensex crossed its 35,000 mark for the first time and stood higher by 311 points (up 0.9%).

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

The ONLY Thing You Need to Know About Bitcoin(The 5 Minute Wrapup)

Jan 6, 2018

You either want it or you want to get as far away from it as possible - but Bitcoin is just the noise masking the REAL opportunity. Read about it here...

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. - ASTRAZENECA PHARMA COMPARISON

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS